Go Pro
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel Free CYCN Stock Alerts

Cyclerion Therapeutics (CYCN) Competitors

Cyclerion Therapeutics logo
$3.50 -0.12 (-3.31%)
Closing price 07/24/2026 04:00 PM Eastern
Extended Trading
$3.48 -0.02 (-0.43%)
As of 07/24/2026 06:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

CYCN vs. OKYO, IMA, SCLX, ANVS, and TCRX

Should you buy Cyclerion Therapeutics stock or one of its competitors? MarketBeat compares Cyclerion Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclerion Therapeutics include OKYO Pharma (OKYO), ImageneBio (IMA), Scilex (SCLX), Annovis Bio (ANVS), and TScan Therapeutics (TCRX). These companies are all part of the "pharmaceutical products" industry.

How does Cyclerion Therapeutics compare to OKYO Pharma?

Cyclerion Therapeutics (NASDAQ:CYCN) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cyclerion Therapeutics has higher revenue and earnings than OKYO Pharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.32-$3.53M-$1.36N/A
OKYO PharmaN/AN/A-$4.71MN/AN/A

Cyclerion Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.06, indicating that its stock price is 94% less volatile than the broader market.

OKYO Pharma has a consensus price target of $5.67, indicating a potential upside of 265.59%. Given OKYO Pharma's stronger consensus rating and higher possible upside, analysts plainly believe OKYO Pharma is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
OKYO Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

OKYO Pharma has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. OKYO Pharma's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -62.10% -55.14%
OKYO Pharma N/A N/A N/A

In the previous week, OKYO Pharma had 14 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 15 mentions for OKYO Pharma and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat OKYO Pharma's score of -0.05 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
OKYO Pharma Neutral

Summary

OKYO Pharma beats Cyclerion Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to ImageneBio?

Cyclerion Therapeutics (NASDAQ:CYCN) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

Cyclerion Therapeutics has higher revenue and earnings than ImageneBio. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.32-$3.53M-$1.36N/A
ImageneBio$800K74.42-$45.35M-$5.79N/A

ImageneBio has a consensus target price of $30.00, indicating a potential upside of 436.67%. Given ImageneBio's stronger consensus rating and higher probable upside, analysts clearly believe ImageneBio is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
ImageneBio
2 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.00

ImageneBio has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. ImageneBio's return on equity of -38.96% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -62.10% -55.14%
ImageneBio N/A -38.96%-34.60%

In the previous week, ImageneBio had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for ImageneBio and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat ImageneBio's score of 1.43 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
ImageneBio Positive

75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of ImageneBio shares are owned by institutional investors. 34.3% of Cyclerion Therapeutics shares are owned by insiders. Comparatively, 2.2% of ImageneBio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cyclerion Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Summary

ImageneBio beats Cyclerion Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Scilex?

Cyclerion Therapeutics (NASDAQ:CYCN) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Scilex
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Scilex had 1 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 2 mentions for Scilex and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Scilex's score of 1.25 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
Scilex Positive

Cyclerion Therapeutics has a net margin of -170.11% compared to Scilex's net margin of -1,110.17%. Scilex's return on equity of 0.00% beat Cyclerion Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -62.10% -55.14%
Scilex -1,110.17%N/A -143.55%

Cyclerion Therapeutics has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market. Comparatively, Scilex has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Cyclerion Therapeutics has higher earnings, but lower revenue than Scilex. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.32-$3.53M-$1.36N/A
Scilex$30.25M1.92-$358.73M-$40.47N/A

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by company insiders. Comparatively, 4.5% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cyclerion Therapeutics beats Scilex on 9 of the 13 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to Annovis Bio?

Cyclerion Therapeutics (NASDAQ:CYCN) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Cyclerion Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Annovis Bio has a net margin of 0.00% compared to Cyclerion Therapeutics' net margin of -170.11%. Cyclerion Therapeutics' return on equity of -62.10% beat Annovis Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Cyclerion Therapeutics-170.11% -62.10% -55.14%
Annovis Bio N/A -318.08%-215.47%

Annovis Bio has a consensus target price of $11.67, indicating a potential upside of 604.93%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts plainly believe Annovis Bio is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Annovis Bio
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
2.60

Cyclerion Therapeutics has higher revenue and earnings than Annovis Bio. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cyclerion Therapeutics$2.07M7.32-$3.53M-$1.36N/A
Annovis BioN/AN/A-$28.85M-$1.71N/A

75.6% of Cyclerion Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 34.3% of Cyclerion Therapeutics shares are held by insiders. Comparatively, 20.8% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Annovis Bio. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Annovis Bio. Cyclerion Therapeutics' average media sentiment score of 1.89 beat Annovis Bio's score of 0.00 indicating that Cyclerion Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Cyclerion Therapeutics Very Positive
Annovis Bio Neutral

Summary

Cyclerion Therapeutics beats Annovis Bio on 10 of the 16 factors compared between the two stocks.

How does Cyclerion Therapeutics compare to TScan Therapeutics?

TScan Therapeutics (NASDAQ:TCRX) and Cyclerion Therapeutics (NASDAQ:CYCN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

In the previous week, TScan Therapeutics had 2 more articles in the media than Cyclerion Therapeutics. MarketBeat recorded 3 mentions for TScan Therapeutics and 1 mentions for Cyclerion Therapeutics. Cyclerion Therapeutics' average media sentiment score of 1.89 beat TScan Therapeutics' score of 0.44 indicating that Cyclerion Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
TScan Therapeutics Neutral
Cyclerion Therapeutics Very Positive

TScan Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Cyclerion Therapeutics has a beta of 1.74, indicating that its share price is 74% more volatile than the broader market.

Cyclerion Therapeutics has lower revenue, but higher earnings than TScan Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TScan Therapeutics$10.32M5.03-$129.77M-$0.96N/A
Cyclerion Therapeutics$2.07M7.32-$3.53M-$1.36N/A

Cyclerion Therapeutics has a net margin of -170.11% compared to TScan Therapeutics' net margin of -1,360.61%. Cyclerion Therapeutics' return on equity of -62.10% beat TScan Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TScan Therapeutics-1,360.61% -91.94% -50.15%
Cyclerion Therapeutics -170.11%-62.10%-55.14%

TScan Therapeutics currently has a consensus target price of $6.00, suggesting a potential upside of 655.67%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe TScan Therapeutics is more favorable than Cyclerion Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TScan Therapeutics
1 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.33
Cyclerion Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 6.3% of TScan Therapeutics shares are held by company insiders. Comparatively, 34.3% of Cyclerion Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

TScan Therapeutics beats Cyclerion Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Cyclerion Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CYCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYCN vs. The Competition

Export
MetricCyclerion TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.16M$3.67B$7.06B$12.20B
Dividend YieldN/A2.19%2.67%9.42%
P/E Ratio-2.5721.2927.1423.63
Price / Sales7.32297.78582.29111.97
Price / CashN/A153.8949.8158.78
Price / Book1.527.8810.286.01
Net Income-$3.53M$23.86M$3.60B$331.99M
7 Day Performance-3.85%-3.82%-1.27%-0.63%
1 Month Performance3.55%-4.45%-1.67%-3.04%
1 Year Performance22.38%33.01%18.25%13.30%

Cyclerion Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYCN
Cyclerion Therapeutics
1.4417 of 5 stars		$3.50
-3.3%		N/A+22.4%$15.16M$2.07MN/A30
OKYO
OKYO Pharma
1.915 of 5 stars		$1.54
+6.7%		$5.67
+268.7%		-43.6%$62.29MN/AN/A7
IMA
ImageneBio
2.6188 of 5 stars		$5.79
-3.6%		$26.50
+358.1%		-67.4%$61.63MN/AN/A70
SCLX
Scilex
0.5519 of 5 stars		$7.22
-7.9%		N/A-42.8%$61.52M$33.86MN/A80
ANVS
Annovis Bio
2.6365 of 5 stars		$1.74
-0.9%		$11.67
+572.4%		-43.2%$60.11MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CYCN) was last updated on 7/26/2026 by MarketBeat.com Staff.
From Our Partners
The pact that ran the world and dollar just expired
In 1974, a U.S.-Saudi deal tied oil sales exclusively to dollars, forcing nations worldwide to hold dollars an...
Golden Portfolio | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
BlackRock's $2.8B Clue (most investors missed)
BlackRock's new fund on the emerging financial grid hit 2.8 billion in assets in just three months, according ...
Awesomely | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
August 6 could be a BIG day for one AI company
One AI company's revenue has surged 757 percent in the past year, earning it an A rating from Louis Navellier'...
InvestorPlace | Sponsoredtc pixel
This tiny piece of glass could be bigger than GPUs
Jensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...
Brownstone Research | Sponsoredtc pixel
The Starlink of Energy
A portable energy unit - already used by the U.S. Navy for decades - is now drawing serious attention from Big...
Monument Traders Alliance | Sponsoredtc pixel